← Galapagos NV (GLPG) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Galapagos NV (GLPG)
Biotechnology · market cap $1.9B · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
15
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Galapagos NV (GLPG) is a Belgian biotechnology company with 704 employees and a market cap of approximately $1.9B at ~$28.81/share. Its lead clinical asset is filgotinib in Phase 3 for Crohn's Disease, supported by a broad but early-stage pipeline spanning cystic fibrosis, dermatomyositis, IPF, rheumatoid arthritis, ulcerative colitis, systemic sclerosis, and osteoarthritis — the majority at Phase 2. The data picture is sparse: no upcoming catalysts are calendared, no recent catalysts are on record, and financial details including cash, runway, and dilution are not disclosed in available facts.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| GLPG2737 | Phase 2 | Cystic Fibrosis |
| GLPG3667 | Phase 2 | Dermatomyositis |
| GLPG2222 50 mg | Phase 2 | Cystic Fibrosis |
| GLPG1205 | Phase 2 | Idiopathic Pulmonary Fibrosis |
| Filgotinib | Phase 3 | Crohn's Disease |
| GLPG3970 | Phase 2 | Rheumatoid Arthritis |
| GLPG1837 dose 1 | Phase 2 | Cystic Fibrosis |
| GLPG0974 | Phase 2 | Ulcerative Colitis |
| GLPG2222 150 mg q.d. | Phase 2 | Cystic Fibrosis |
| GLPG1837 dose 2 | Phase 2 | Cystic Fibrosis |
| GLPG1690 600 mg QD | Phase 2 | Idiopathic Pulmonary Fibrosis |
| GLPG0634 | Phase 2 | Rheumatoid Arthritis |
| GLPG1690 | Phase 2 | Systemic Sclerosis |
| GLPG1972 | Phase 2 | Osteoarthritis |
| GLPG0259 oral capsule | Phase 2 | Rheumatoid Arthritis |
Price & technical context
3-month
-16.8%
6-month
-7.0%
12-month
+6.1%
52-wk range
$25.07–$37.62
vs 50-day MA
-5.4%
vs 200-day MA
-10.4%
Realized vol
30.1%
Max drawdown
-27.1%
Daily closes through 2026-05-06. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GLPG (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 15 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.